Weekly Recap: CLN—978 Dec 2026 data release and HC Wainwright $35 target

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) said it will report December 2026 single— and multi—dose CLN—978 data for refractory SLE, hard—to—treat RA and refractory Sjögren’s—with the multi—dose readout flagged as a Q4 2026 milestone—after HC Wainwright raised its price target on CGEM to $35 from $3…